肾移植术后撤除环孢素A的观察和体会  

Assessment of cyclosporine A withdrawal in renal allograft transplant recipients

作　　者：寿张飞[1] 陈江华[1] 王逸民[1] 张建国[1] 王苏娅[1] 吴建永[1] 朱琮[1] 

机构地区：[1]浙江医科大学附属第一医院肾移植血液净化中心

出　　处：《中华器官移植杂志》1999年第3期146-147,共2页Chinese Journal of Organ Transplantation

摘　　要：目的总结肾移植术后因某些原因而撤除环孢素Ａ（ＣｓＡ）的经验教训，并对其可行性及安全性进行评价。方法总结２０例术后撤除ＣｓＡ的肾移植患者的有关资料。结果２０例患者在撤除ＣｓＡ并同时调整其它免疫抑制剂剂量后，其肾功能、肝功能及白细胞计数等与撤药前比较，差异均无显著性；与同期常规治疗者比较，两组肾功能的差异也无显著性。结论在调整其它免疫抑制剂剂量的前提下，逐步减少ＣｓＡ的用量并最终撤除ＣｓＡ，可以是安全的，但并不提倡，因为使用ＣｓＡ，利大于弊，若确需撤ＣｓＡ。Objective To assess the safety and feasibility of cyclosporine A (CsA) withdrawal for some causes after kidney transplantation. Methods The data for 20 renal allograft recipients who withdrew CsA from normal triple immunosuppressive regime under the guide of transplant experts were retrospectively analyzed. Results All patients survived with steady graft function till now. No significant difference in serum creatine, ALT levels and WBC count was found between prewithdrawal and postwithdrawal of CsA. As compared kidney function of 10 CsAwithdrawn and survived more than 5 years' patients with the results of other 13 patients transplanted during the corresponding period, there were no significant difference also. Conclusion Under the regulation of other immunosuppressive doses, it is safety that CsA dose was gradually decreased and finally withdrawn. Meanwhile it should be emphasized that,though CsA had certain side effects,it was not recommended to withdraw CsA willfully, because the advantages of CsA therapy certainly surpassed its disadvantages.

关 键 词：肾移植 撤药综合征 环孢素A 

分 类 号：R699.2[医药卫生—泌尿科学]